Heinrich Wieland Prize: Closing in on the cause of diabetes

Boehringer IngelheimFor his milestone discoveries on the development of diabetes, Prof. Markus Stoffel from the Institute of Molecular Systems Biology at the ETH Zurich was awarded the Heinrich Wieland Prize, one of the most treasured science awards in Germany. He received the distinction with EUR 50,000 prize money for his work in deciphering important mechanisms of blood sugar regulation and lipid metabolism in the body.

During the award ceremony at the Ludwig-Maximillians-Universität in Munich, the renowned internist with a research focus on nutrition Prof. Nepomuk Zöllner was honored, as well, with the Heinrich Wieland "Medal in Gold" for his lifetime achievement in gout research.

Professor Stoffel (46), tenured since 2006 at the ETH Zürich, discovered two fundamental biochemical signaling pathways in cells. When these break down, type 2 diabetes, which affects 90 percent of all patients with diabetes, can develop. In people with type 2 diabetes, an insulin sensor in the liver malfunctions, thus preventing the organ from reacting properly to the blood sugar reducing hormone insulin. Prof. Stoffel also showed that so-called microRNAs control cholesterol production in the liver and insulin secretion in the pancreas. As such, they could also play a role in diabetes. The metabolism expert is convinced that, "in the future, insulin sensors and microRNAs might provide points of attack for novel drugs in treating type 2 diabetes."

"Even though we have good treatments for diabetes today, there is still much to learn about the molecular causes and mechanisms of this widespread condition," remarked Professor Konrad Sandhoff, Chairman of the Board of Trustees in recognition of the laureate's achievements. However, the medical researcher's work still falls in the realm of basic research, making quick breakthroughs in therapeutic applications unlikely.

"We are awarding the Heinrich Wieland Prize in appreciation of the fruits borne by basic research in recent years, especially in the field of diabetes," declared Dr Andreas Barner, Vice Chairman of the Board of Managing Directors and Head of Research, Development and Medicine at Boehringer Ingelheim. "This is the kind of basic research that is going to drive the development of tomorrow's medicine. Professor Stoffel's findings are even more significant in light of the growing numbers of diabetic patients worldwide, expected to reach 366 million by 2030."

The Heinrich Wieland Prize has been awarded annually since 1964 in honor of the German chemist, lipid researcher and Nobel Prize winner Prof. Heinrich Otto Wieland (1877 to 1957). Professor Wieland was associated with Boehringer Ingelheim and founded the company's first scientific research department. The Heinrich Wieland Prize distinguishes exceptional scientific work in metabolism research. An independent Board of Trustees selects the prizewinner.

The Heinrich Wieland Medal in Gold is awarded in recognition of the lifetime achievement of an outstanding scientist. Professor Nepomuk Zöllner is only the fourth laureate of this prize, which was bestowed on him in recognition of his work as one of the most productive gout researchers. The 85-year old worked for 30 years at the Ludwig-Maximilians-Universität in Munich and, as a result of his exceptional clinical and experimental research work, is one of the most highly regarded experts in his field.

Prof Nepomuk Zöllner was Chairman of the Board of Trustrees of the Heinrich Wieland Prize from 1996 until 2006 and was succeeded by Prof Konrad Sandhoff in 2006.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 135 affiliates in 47 countries and 39,800 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.

In 2007, Boehringer Ingelheim posted net sales of 10.9 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

Most Popular Now

FDA grants Breakthrough Therapy Designation to Pfi…

Pfizer Inc. (NYSE:PFE) today announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designat...

Novartis invests in early technical development ca…

Novartis today announced it is investing in next-generation biotherapeutics with the creation of a fully integrated, dedicated USD 300m scientific environment that will b...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a 30-µg booster dose of their Omicron BA.4/BA.5 bivalent-adapted COVID-19 vaccine (COMIRNATY® Original/Om...

Malaria booster vaccine shows durable high efficac…

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of ...

Strict COVID lockdowns in France improved cardiova…

A new paper in European Heart Journal - Digital Health, published by Oxford University Press, indicates that social-distancing measures like total lockdown have a measura...

U.S. clinical trial evaluating antiviral for monke…

A Phase 3 clinical trial evaluating the antiviral tecovirimat, also known as TPOXX, is now enrolling adults and children with monkeypox infection in the United States. St...

Stem cell-gene therapy shows promise in ALS safety…

Cedars-Sinai investigators have developed an investigational therapy using support cells and a protective protein that can be delivered past the blood-brain barrier. This...

Drug turns cancer gene into "eat me" fla…

Tumor cells are notoriously good at evading the human immune system; they put up physical walls, wear disguises and handcuff the immune system with molecular tricks. Now...

Mucosal antibodies in the airways protect against …

High levels of mucosal antibodies in the airways reduce the risk of being infected by omicron, but many do not receive detectable antibodies in the airways despite three ...

WHO grants prequalification to GSK's Mosquirix - t…

GSK plc (LSE/NYSE: GSK) announced that the World Health Organization (WHO) has awarded prequalification to Mosquirix (also known as RTS,S/AS01), GSK's groundbreaking mala...

Bird's enzyme points toward novel therapies

Thank the rare crested ibis for a clue that could someday help our bodies make better drugs. The species of bird is the only one known to naturally produce an enzyme ...

WHO strongly advises against antibody treatments f…

The antibody drugs sotrovimab and casirivimab-imdevimab are not recommended for patients with COVID-19, says a WHO Guideline Development Group of international experts in...